Abbott Laboratories (ABT)
| Market Cap | 186.79B |
| Revenue (ttm) | 44.33B |
| Net Income (ttm) | 6.52B |
| Shares Out | 1.74B |
| EPS (ttm) | 3.72 |
| PE Ratio | 28.88 |
| Forward PE | 18.93 |
| Dividend | $2.52 (2.35%) |
| Ex-Dividend Date | Jan 15, 2026 |
| Volume | 21,813,864 |
| Open | 108.27 |
| Previous Close | 108.61 |
| Day's Range | 106.08 - 110.05 |
| 52-Week Range | 105.78 - 141.23 |
| Beta | 0.72 |
| Analysts | Strong Buy |
| Price Target | 142.50 (+32.66%) |
| Earnings Date | Jan 22, 2026 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.52 billion, a decrease of -51.13%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for ABT stock is "Strong Buy." The 12-month stock price target is $142.5, which is an increase of 32.66% from the latest price.
News
Is The Fall In Abbott Stock Justified?
Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, align...
Abbott Laboratories: Buy This Dividend King On Sale Now
Last month, Abbott Laboratories hiked its dividend for the 54th consecutive year. The company's FreeStyle Libre and Volt PFA System franchises, as well as its pending acquisition of Exact Sciences, po...
Abbott faces India scrutiny in cough syrup abuse investigation, documents show
Indian drugmaker Abbott Healthcare's supply chain is being scrutinised as part of a wider investigation into the alleged misuse of its codeine-based cough syrup which is prone to abuse by addicts, doc...
Abbott Laboratories Raised Prices, Prompting Sales Slump
The medical-products maker's shares tumbled after its quarterly profit and sales underwhelmed investors.
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Thursday.
MRNA Rallies on Cancer Vaccine Trial, PG Mixed Earnings, ABT Sell-Off
Intel's (INTC) recent rally isn't the only one investors should pay attention to, says Diane King Hall. She points to Moderna (MRNA) hitting a 52-week high after a trial drug to treat melanoma posted ...
Cramer's Mad Dash: Abbott Labs
CNBC's Jim Cramer delivers his daily Mad Dash.
Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints
Abbott Laboratories (NYSE: ABT) stock fell on Thursday after the company reported fourth-quarter 2025 sales and the first-quarter 2026 earnings outlook below expectations.
Abbott Stock Slumps on Earnings. What's Weighing on the Medical Devices Maker.
Abbott reports fourth-quarter sales that miss analysts' estimates.
Abbott misses quarterly revenue estimates on weakness in diagnostics segment
Abbott missed Wall Street estimates for quarterly revenue on Thursday, hit by weakness in its diagnostic business which has been volatile due to sharp decline in COVID-19 testing demand and a freeze o...
Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook
Fourth-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.50 reflects growth of 12 percent Full-year 2025 GAAP diluted EPS of $3.72; adjusted diluted EPS of $5.15 reflects growth of 10 perc...
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q4 Earnings
Abbott Laboratories (NYSE: ABT) will release earnings for the fourth quarter before the opening bell on Thursday, Jan. 22.
Polen Focus Growth Portfolio Q4 2025 Performance, Attribution & Portfolio Activity
Eli Lilly's stock price has underperformed this year, much of it on the back of drug pricing concerns, potential tariff impacts and, perhaps, less enthusiasm for GLP-1 drugs. The primary drag for the ...
Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms
Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, is designed with dual-energy to treat atrial fibrillation patients with the most challenging cases It can deliver both radiofrequency energy...
Abbott Laboratories: Q4 Earnings On The Horizon
Abbott Laboratories has been essentially flat over the last 15 months, underperforming the S&P 500's 17.5% total return. Q3 2025 results showed normalized EPS in line at $1.30, with revenue up nearly ...
Abbott: Not Cheap, But Built To Compound In Uncertain Markets
Abbott Laboratories is a defensive, high-quality compounder with a premium valuation justified by recurring cash flow and strong medical device platforms. Medical Devices, especially Diabetes Care (Li...
Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy
The two properties strengthen the Company's presence in Illinois, where it currently owns and manages three other properties. LAS VEGAS, NEVADA / ACCESS Newswire / January 7, 2026 / Sentinel Net Lease...
Abbott hosts conference call for fourth-quarter earnings
ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens.
Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions
Traditional food logging apps offer feedback after the fact—Libre Assist1 offers help in-the-moment to inform mealtime decisions before every bite Libre Assist1 leverages AI to predict how food choice...
Best Dividend Aristocrats For January 2026
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%...
Best Dividend Kings: December 2025
Dividend Kings underperformed SPY in 2025, up 4.47% vs. SPY's 17.7%, but select Kings outperformed the index. Twenty-two Dividend Kings are identified as both potentially undervalued and offering long...
Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January
Chevron (CVX) is expected to extend its dividend growth streak to 39 years, but with a muted 3–4% increase amid lower oil prices. CVX's earnings remain under pressure from declining oil prices despite...
Abbott Laboratories Shrugs Off Tariffs And China Headwinds With A 7% Dividend Raise
Abbott Laboratories (ABT) earns a buy rating for its operational resilience, robust fundamentals, and strong dividend growth despite headwinds. ABT delivered double-digit EPS growth, solid Medical Dev...
Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation
Abbott's Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation – or PF...